Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cosmin A Tegla

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
JAAD Case Reports|June 17, 2024
Diffuse large B-cell lymphoma with cutaneous involvement in a patient with xeroderma pigmentosum type CMelissa R Laughter, Cosmin A Tegla, Shashi Pawar, et al.
Journal of Neuroimmunology|July 7, 2009
Neuroprotective effects of the complement terminal pathway during demyelination: implications for oligodendrocyte survivalCosmin A Tegla, Cornelia Cudrici, Violeta Rus, et al.
Immunologic Research|August 19, 2011
Membrane attack by complement: the assembly and biology of terminal complement complexesCosmin A Tegla, Cornelia Cudrici, Snehal Patel, et al.
Experimental and Molecular Pathology|January 24, 2009
Response gene to complement 32 is required for C5b-9 induced cell cycle activation in endothelial cellsMatthew Fosbrink, Cornelia Cudrici, Cosmin A Tegla, et al.
Archivum Immunologiae Et Therapiae Experimentalis|April 1, 2008
Role of response gene to complement 32 in diseasesSonia I Vlaicu, Cornelia Cudrici, Takahiro Ito, et al.
Immunologic Research|December 19, 2012
Role of C5b-9 complement complex and response gene to complement-32 (RGC-32) in cancerSonia I Vlaicu, Cosmin A Tegla, Cornelia D Cudrici, et al.
Immunologic Research|October 5, 2014
Role of SIRT1 in autoimmune demyelination and neurodegenerationAlvaro Martin, Cosmin A Tegla, Cornelia D Cudrici, et al.
Experimental and Molecular Pathology|January 23, 2017
SIRT1 as a potential biomarker of response to treatment with glatiramer acetate in multiple sclerosisDaniel Hewes, Alexandru Tatomir, Adam M Kruszewski, et al.
Experimental and Molecular Pathology|November 4, 2009
Epigenetic modifications induced by RGC-32 in colon cancerSonia I Vlaicu, Cosmin A Tegla, Cornelia D Cudrici, et al.
Experimental and Molecular Pathology|September 27, 2015
RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosisAdam M Kruszewski, Gautam Rao, Alexandru Tatomir, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
JAAD Case Reports|June 17, 2024
Diffuse large B-cell lymphoma with cutaneous involvement in a patient with xeroderma pigmentosum type CMelissa R Laughter, Cosmin A Tegla, Shashi Pawar, et al.
Journal of Neuroimmunology|July 7, 2009
Neuroprotective effects of the complement terminal pathway during demyelination: implications for oligodendrocyte survivalCosmin A Tegla, Cornelia Cudrici, Violeta Rus, et al.
Immunologic Research|August 19, 2011
Membrane attack by complement: the assembly and biology of terminal complement complexesCosmin A Tegla, Cornelia Cudrici, Snehal Patel, et al.
Experimental and Molecular Pathology|January 24, 2009
Response gene to complement 32 is required for C5b-9 induced cell cycle activation in endothelial cellsMatthew Fosbrink, Cornelia Cudrici, Cosmin A Tegla, et al.
Archivum Immunologiae Et Therapiae Experimentalis|April 1, 2008
Role of response gene to complement 32 in diseasesSonia I Vlaicu, Cornelia Cudrici, Takahiro Ito, et al.
Immunologic Research|December 19, 2012
Role of C5b-9 complement complex and response gene to complement-32 (RGC-32) in cancerSonia I Vlaicu, Cosmin A Tegla, Cornelia D Cudrici, et al.
Immunologic Research|October 5, 2014
Role of SIRT1 in autoimmune demyelination and neurodegenerationAlvaro Martin, Cosmin A Tegla, Cornelia D Cudrici, et al.
Experimental and Molecular Pathology|January 23, 2017
SIRT1 as a potential biomarker of response to treatment with glatiramer acetate in multiple sclerosisDaniel Hewes, Alexandru Tatomir, Adam M Kruszewski, et al.
Experimental and Molecular Pathology|November 4, 2009
Epigenetic modifications induced by RGC-32 in colon cancerSonia I Vlaicu, Cosmin A Tegla, Cornelia D Cudrici, et al.
Experimental and Molecular Pathology|September 27, 2015
RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosisAdam M Kruszewski, Gautam Rao, Alexandru Tatomir, et al.
Pageof 2